Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 first-line furmonertinib versus platinum-based chemotherapy in EGFR exon 20 insertion non-small cell lung cancer
MOH_2023-03-09_012413Phase 3Not yet recruiting
- Sponsor
- ArriVent BioPharma
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of furmonertinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by ArriVent BioPharma. Primary endpoint: Progression-free survival. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2023-03-09_012413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-03-09_012413.